Recently thyroxine analogs have enjoyed great attention among workers interested in the modus operandi of the thyroid hormones on a molecular level. It is apparent that some of these compounds, while calorigenically inactive themselves, may serve as specific antagonists of thyroid hormones (1). Others are effective as therapeutic agents in bringing about changes in lipid metabolism in patients with idiopathic hypercholesterolemia and atherosclerotic heart disease (2, 3). At the moment, there are no less than five analogs of widely different structures advocated by various investigators as being the most effective agents to lower serum cholesterol: D-thyroxine (3, 4); 3,5,3',5'-tetraiodothyroformic acid (4, 5); 3,5,3'-triiodothyropropionic acid (6); 3,5,3'-triiodothyroacetic acid (2); and 3,5-diiodothyroacetic acid (7). As these and other analogs are rapidly gaining considerable clinical usage, the metabolic study of these compounds has lagged behind. We still have much to learn of 1 ) the fate of some of these compounds in the animal body, 2) the factors other than side chain differences which may be responsible for a lower calorigenic activity than the parent compounds, and 3) their effects on metabolism of the individual tissues. This report summarizes our results concerning the calorigenic effect of some thyroxine analogs on the diaphragm, heart, kidney, and liver as compared to that on the animal basal metabolic rate. temperature room at 25°C. All the animals were approximately 6 weeks post surgical thyroidectomy at the start of each experiment. Every animal was checked for completeness of thyroidectomy during autopsy.
THE CALORIGENIC EFFECTS OF SOME THYROXINE ANALOGS ON INTACT ANIMALS AND ON EXCISED TISSUES
Recently thyroxine analogs have enjoyed great attention among workers interested in the modus operandi of the thyroid hormones on a molecular level. It is apparent that some of these compounds, while calorigenically inactive themselves, may serve as specific antagonists of thyroid hormones (1) . Others are effective as therapeutic agents in bringing about changes in lipid metabolism in patients with idiopathic hypercholesterolemia and atherosclerotic heart disease (2, 3) . At the moment, there are no less than five analogs of widely different structures advocated by various investigators as being the most effective agents to lower serum cholesterol: D-thyroxine (3, 4); 3,5,3',5'-tetraiodothyroformic acid (4, 5) ; 3,5,3'-triiodothyropropionic acid (6); 3,5,3'-triiodothyroacetic acid (2) ; and 3,5-diiodothyroacetic acid (7) . As these and other analogs are rapidly gaining considerable clinical usage, the metabolic study of these compounds has lagged behind. We still have much to learn of 1 ) the fate of some of these compounds in the animal body, 2) the factors other than side chain differences which may be responsible for a lower calorigenic activity than the parent compounds, and 3) their effects on metabolism of the individual tissues. This report summarizes our results concerning the calorigenic effect of some thyroxine analogs on the diaphragm, heart, kidney, and liver as compared to that on the animal basal metabolic rate. Thyroxine and all of the analogs 1 were first dissolved in 0.1 N NaOH, then diluted with saline to the desired concentration of analog. The final concentration of NaOH was 0.02 N, and 0.9 per cent NaCl solution, also containing 0.02 N NaOH, was employed as a control injection. All 
METHODS

General
RESULTS
Barker and Klitgaard found in 1952 (12) that, when a host animal was pretreated with large doses of thyroid hormones, the excised brain, lymphatics, and gonads did not show any calorigenic response. Therefore, the present study was limited to the excised diaphragm, heart, kidney, and liver. Our average control BMR for the thyroidectomized animals was 103.6 ml oxygen per 100 g per hour. The control Qo2 for excised tissues was 0.86, 1.84, 3.54, and 1.28 Ml oxygen per mg per hour for diaphragm, heart, kidney, and liver, respectively. L-Thyroxine jiM/kg. Figure 1 . When L-thyroxine was given in dosage greater than 1.5 mmoles per kg per day, the activity of the agitated animals contributed to the sharp increase of oxygen demand, and the metabolic rate obtained, no longer basal, rose much faster than the Qo2 of excised tissues with further increases of thyroxine. In the lower dosage range, the increase of oxygen consumption of the intact animal and that of the excised tissues were close if both were expressed as per cent of control.
A similar comparison of the calorigenic action of 3,5,3'-triiodothyropropionic acid is shown in Figure 2 . As compared to L-thyroxine, 3,5,3'-triiodothyropropionic acid showed a much weaker calorigenic action, approximately half that of L-thyroxine. The response of the intact animal and of diaphragm, liver, and kidney correlated very well up to the highest testing dose, 3.84 Mmoles per kg per day. Barker (13) Table I shows the ratios of the metabolic responses of heart to those of diaphragm, kidney, and liver. The compounds studied included the L-and D-isomers of thyroxine and 3,5,3'-triiodothyronine as well as their propionic and acetic acid analogs, several of which have been used on patients with atherosclerotic heart disease.
In Table I We studied six additional thyroxine analogs with iodination at positions 3,3' or 3,3',5', bearing only one iodine substitution on the inner ring. Not only do these compounds exhibit less than 3 per cent of thyroxine calorigenic activity (18), but they have been found to be effective antagonists of the calorigenic action of thyroxine in athyreotic rats (1) and in human subjects (19) . The results in Table II Table II) , none of the tissues showed a definite rise of oxygen consumption (probability greater than 0.05) in response to any of these six analogs.
DISCUSSION
It is generally assumed that the contribution of any individual organ to the whole animal BMR is a function of its characteristic rate of cellular metabolism and its mass. Precise correlation is difficult, since the oxygen consumption of excised tissue is not necessarily representative of the oxygen consumption of tissue in vivo, even under a resting state. During the usual manometric procedure, neither the tone nor the integrity of heart or striated muscle is maintained. In fact, the oxygen consumption of these tissues measured in the first half hour is often significantly higher than that obtained in the second half hour, indicating deterioration with time. Nevertheless, our results show that the increased Qo2 of excised diaphragm, heart, kidney, and liver parallels the change of whole animal BMR, with the response of heart being somewhat more intense.
In a careful study of 150 thyrotoxic patients, Sandler and Wilson (20) showed that thyrotoxicosis may act as the determining factor precipitating serious disturbance of cardiac function and rhythm, particularly in the presence of associated heart disease. Many other investigators have observed that angina pectoris could be induced by thyroxine analogs as well as by the thyroid hormones themselves (4, 21). Boyd and Oliver (4) studied the effect of several D-isomers and fatty acid analogs of thyroid hormones on the serum cholesterol of euthyroid men with ischemic heart disease and hypercholesterolemia. During their study angina appeared in 34 patients, 14 of whom showed no discernible elevation of BMR. Greene, Pearce and Rideout (22) also observed angina pectoris without measurable change of BMR in a healthy physician serving as control during their study of 3,5,3'-triiodothyroacetic acid.
Our findings on the excised tissues offerja possible explanation for these clinical observations. The L-and D-isomers of both thyroid hormones, as well as their propionic and acetic acid analogs, consistently showed a larger stimulatory effect on heart tissue metabolism than on that of diaphragm, kidney, or liver. Assuming that in a "70 kilo man" the heart weighs 400 g, or 0.6 per cent of the body weight, an appreciable elevation in the cardiac metabolism in vivo would not be reflected by measurements of the entire BMR. Thus, thyroxine and its analogs at low dosage may conceivably increase the oxygen demand of the heart without measurable effect on whole body BMR.
The interaction of thyroxine analogs and catecholamines may offer an alternate explanation, but has not been completely explored. In a preliminary report, Wiswell, Hurwitz, Coronho and Bing (23) suggested that in thyrotoxicosis the metabolism of catecholamines might be altered. The metabolism of catecholamines may also be altered in patients given thyroxine analogs, although such a study is not yet available. It is entirely possible that these compounds may produce relative myocardial ischemia and angina pectoris through potentiation of catecholamines, even in euthyroid patients.
The therapeutic value of lowering the levels of serum and liver cholesterol is currently still in dispute and it is outside the scope of this report to comment on the individual merit of the various thyroxine analogs as achieving such a state. Suffice it to say that avoidance of myocardial ischemia is paramount in the treatment and management of patients with atherosclerotic heart disease. The value of any therapy which may increase myocardial ischemia, relative or absolute, must be questioned. Our results show that heart tissue itself is very sensitive to the calorigenic effect of several of the thyroxine analogs which are currently popular as therapy for hypercholesterolemia and atherosclerotic heart disease. Therefore, while some thyroxine analogs have been demonstrated to lower the serum and liver cholesterol, the ideal therapeutic agent for atherosclerosis is yet to be found.
SUMMARY
The calorigenic effects of thyroxine and 13 of its analogs were studied in thyroidectomized animals as well as in excised diaphragm, heart, kidney, and liver. Within moderate dosage range, both experimental procedures gave comparable results. None of the analogs showed a truly unique effect on any of the four tissues, although the response of heart was consistently higher than that of the other tissues. Attention is called to reports that a considerable proportion of patients given thyroxine analogs for reduction of serum cholesterol may experience angina pectoris without measurable elevation of basal metabolism rate. Our findings on cardiac tissue metabolism may furnish the basis for this clinical observation.
